Last reviewed · How we verify
oral contraceptives
Oral contraceptives prevent pregnancy by suppressing ovulation through hormonal inhibition of the hypothalamic-pituitary-gonadal axis.
Oral contraceptives prevent pregnancy by suppressing ovulation through hormonal inhibition of the hypothalamic-pituitary-gonadal axis. Used for Contraception / prevention of pregnancy, Menstrual cycle regulation, Treatment of acne.
At a glance
| Generic name | oral contraceptives |
|---|---|
| Sponsor | FHI 360 |
| Drug class | Hormonal contraceptive |
| Target | Estrogen receptor, Progesterone receptor |
| Modality | Small molecule |
| Therapeutic area | Contraception / Reproductive Health |
| Phase | FDA-approved |
Mechanism of action
Oral contraceptives contain synthetic estrogen and/or progestin that inhibit the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the pituitary gland, preventing ovulation. They also thicken cervical mucus and alter the endometrium to create a hostile environment for sperm and implantation. The combination of these mechanisms provides contraceptive efficacy of >99% with perfect use.
Approved indications
- Contraception / prevention of pregnancy
- Menstrual cycle regulation
- Treatment of acne
- Endometriosis management
- Polycystic ovary syndrome (PCOS) symptom management
Common side effects
- Nausea
- Headache
- Breast tenderness
- Breakthrough bleeding
- Mood changes
- Venous thromboembolism
- Hypertension
- Weight gain
Key clinical trials
- Estrogen, Diet, Genetics and Endometrial Cancer
- Anxiety and Depression in Adolescent PCOS (NA)
- Polycystic Ovary Syndrome in Type 1 Diabetes
- A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF) (PHASE2)
- Efficacy of Low-dose Percutaneous Electrical Stimulation in Patients With Erectile Dysfunction. (NA)
- A Drug-drug Interaction Study of Vorasidenib and a Combined Oral Contraceptive in Healthy Female Participants (PHASE1)
- A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause (PHASE1)
- The Influence of Combined Oral Contraception on the DEvelopment and progRession of Chronic venoUs diSeases (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- oral contraceptives CI brief — competitive landscape report
- oral contraceptives updates RSS · CI watch RSS
- FHI 360 portfolio CI